[Form 4] Zimmer Biomet Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Lori Winkler, SVP and CHRO of Zimmer Biomet Holdings, Inc. (ZBH), reported a sale of 1,500 shares of the issuer's common stock on 08/18/2025 at a reported price of $102.49 per share. Following the transaction, Winkler beneficially owned 8,333 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/20/2025.

Insights

Financial Analyst

TL;DR: Insider sale of 1,500 shares reduces direct holdings to 8,333 shares; transaction appears routine and non-material based on reported size.

The filing documents a straightforward sale on 08/18/2025 of 1,500 common shares at $102.49 each, leaving a remaining direct beneficial ownership of 8,333 shares. No options, derivatives, or additional transactions are reported. The level of detail is limited to the single disposition and does not present earnings, control changes, or other material events for investors.

Corporate Governance Expert

TL;DR: Form 4 discloses a routine officer sale executed and reported by attorney-in-fact; disclosure compliance appears satisfied.

The report names Lori Winkler as SVP and CHRO and indicates the Form 4 was signed by Matthew R. St. Louis as attorney-in-fact. The filing records a sale (code S) and provides post-transaction ownership. There are no indications of derivative transactions, rule 10b5-1 plan notation, or amendments altering substance. Documentation meets basic Section 16 reporting requirements as presented.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winkler Lori

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and CHRO

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S		1,500	D	$102.49	8,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Lori Winkler (power of attorney previously filed)	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Lori Winkler report on Form 4 for ZBH?

She reported a sale of 1,500 shares of Zimmer Biomet Holdings common stock on 08/18/2025 at a reported price of $102.49 per share.

How many ZBH shares does Lori Winkler beneficially own after the reported transaction?

8,333 shares are reported as beneficially owned following the transaction.

When was the Form 4 signed and who signed it?

The Form 4 was signed on 08/20/2025 by Matthew R. St. Louis as attorney-in-fact for Lori Winkler.

Does the filing report any derivative transactions or 10b5-1 plan?

No derivatives or 10b5-1 plan notation are reported in the provided Form 4 content.

What is the reporting person's role at Zimmer Biomet?

Lori Winkler is listed as SVP and CHRO (Senior Vice President and Chief Human Resources Officer) in the filing.